BAXTER INTERNATIONAL INC BAX
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
3.86
Altman Z″ — distress risk · safe
-36.4%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $11.2B | -$957.0M | $3.4B | — | $6.1B |
| 2024 | $10.6B | -$649.0M | $4.0B | — | $7.0B |
| 2023 | $10.4B | $2.7B | $4.2B | — | $8.5B |
| 2022 | $10.1B | -$2.4B | $3.5B | — | $5.9B |
| 2021 | $12.1B | $1.3B | $4.7B | — | $9.1B |
| 2020 | $11.7B | $1.1B | $4.6B | — | $8.7B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.86 (safe)
- Working capital / assets 0.195
- Retained earnings / assets 0.683
- EBIT / assets -0.015
- Equity / liabilities 0.439
Source: SEC EDGAR filings · CIK 0000010456 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.